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Thrombolysis: The Need for a Critical Review* 
ERNEST SCOTT MONRAD, MD 
Bronx, New York 
The (Thrombolysis in Myocardial Infarction) TIMI-1 trial led to 
the hypothesis that the greater reperfusion rate seen with recom-
binant tissue-type plasminogen activator (rt-PA) versus streptoki· 
nase would result in greater reductions in infarct size and mor-
tality in patients with acute myocardial infarction. Despite 
extensive investigation, no trial comparing rt-PA with streptoki-
nase (European Cooperative Study Group, Plasminogen Activator 
Italian Multicenter Study [PAlMS], Gruppo Italiano per lo Studio 
della Sopravvivenze nell'lnfarto Miocardico [GISSI-2], Interna-
tional Study on Infarct Survival [ISIS-3], even TIMI-1 itselO nor 
rt-PA and anisoylated plasminogen-streptokinase activator 
The recently published lead article (1) in a prominent journal 
reported the results of a study on the comparative efficacy of 
two alternative adjunctive therapies (intravenous heparin and 
low dose aspirin) to thrombolytic therapy for acute myocardial 
infarction. As the benefits of concomitant therapy in patients 
with infarction are not well defined and the two drugs are 
commonly used, it was an article with potential widespread 
interest that merited publication in a prominent forum.· 
However, the Heparin-Aspirin Reperfusion Trial (HART) 
(1) carried far greater significance because of its keystone 
position in another debate, the choice of a thrombolytic agent 
for the treatment of acute myocardial infarction, and specifi-
cally the validity of the Gruppo Italiano per lo studio della 
sopravvivenze nell'Infarto Miocardico (GISSI-2) study (2,3). 
Before publication, across-the-country use of the data from the 
HART trial has been used to refute the findings ofGISSI-2 (4). 
Therefore, it would have been preferable that the editorial 
commentary accompanying the article (5) had been an 
independent, balanced (even countervailing) review of the 
subject. Particularly appropriate, given the focus of the 
article, would have been a review by a hematologist. In-
stead, a highly respected investigator, but one with a long-
standing research relation to the parties involved, wrote the 
editorial (5). Although the editorial was a well-written re-
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complex (APSAC or anistreplase) (Bassand, TEAM-3, ISIS-3), 
have confirmed this hypothesis. 
In a reversal of traditional scientific method, the studies, 
rather than the unconfirmed hypothesis, have been rejected. A 
lack of independent review of this subject may have contributed to 
this outcome. It is proposed that standards of review and editorial 
comment mandating true critical distance and independence be 
followed, permitting greater independence of scientific inquiry, 
review and debate. 
(JAm Coli Cardiol1991;18:1573-8) 
view, it did not offer a critical examination of the primary 
article. Thus, the journal failed in its journalistic and edito-
rial responsibility in the selection of editorial comment to 
address the significance of the article. 
The scientific medical community defines for the field of 
medicine the standards of practice, and the medical journals 
are established, through peer review and editorial revision and 
comment, to assure the high quality of those standards. As 
such, they are the moral equivalent of auditors in the commer-
cial world and I believe that their standards of independence 
should be no less rigorous than those of auditors. 
The Auditing Standards Board (6) of the American Insti-
tute of Certified Public Accountants has defined this standard 
as follows: " ... the auditor [must] be independent; ... he 
must be without bias with respect to the client since other-
wise he would lack that impartiality necessary for the 
dependability of his findings, however excellent his technical 
proficiency may be .... It is of utmost importance to the 
profession that the general public maintain confidence in the 
independence of independent auditors. Public confidence 
... might also be impaired by the existence of circum-
stances which reasonable people might believe likely to 
influence independence .... Independent auditors should 
not only be independent in fact; they should avoid situations 
that may lead outsiders to doubt their independence." 
As government financial support for research has been 
reduced, the medical and nonmedical academic world has 
forged closer links to the business world. Because a growing 
proportion of current research effort is being funded by 
pharmaceutical interests, journal review standards must be 
ever more critical to maintain their independence. Yet, 
rather than placing greater emphasis on independent review, 
many journals now even have an editorial policy encourag-
ing authors to suggest the names of reviewers (7). 
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For the past 5 years many studies have been perrormed to 
try to confirm the hypothesis that recombinant tissue plas-
minogen activator (rt-PA) is the thrombolytic agent of choice 
for an evolving acute myocardial infarction (8), that is, to 
assess whether it can reduce the morbidity and mortality 
associated with acute myocardial infarction better than other 
available drugs. 
A critically distanced and independent evaluation in this 
field has been lacking in this country since the results of the 
TIMI-1 trial (9). This lack, and the subsequent selection of 
rt-PA as the sole study drug by the TIMI investigators for the 
next TIMI trials, constituted a de facto endorsement by the 
National Heart, Lung, and Blood Institute of rt-PA as the 
thrombolytic drug of choice. This development has been 
followed by a reversal of the traditional scientific method. 
When investigational trials failed to confirm the hypoth-
esis that rt-PA is the agent of choice for infarction, the trials 
rather than the hypothesis underwent reexamination. Trials 
consonant with this view have been widely promoted, while 
trials contradictory to this have been discounted, some even 
before completion (witness the ISIS-3 trial). Yet, there is a 
significant, decade-long, literature to merit a reconsideration 
of this. 
Principles 
There are currently three approved activators of plasmi-
nogen ("thrombolytic" drugs) for the intravenous therapy of 
acute myocardial infarction: streptokinase, alteplase (recom-
binant tissue-type plasminogen activator [rt-PA]) and an-
isoylated plasminogen-streptokinase activator complex 
(APSAC). All three have undergone extensive investigation 
for their efficacy in acute myocardial infarction, and all have 
been shown to effect coronary patency, preserve myocar-
dium and reduce mortality in the wake of acute myocardial 
infarction. These have become the standard end points for 
assessing the efficacy of these agents, clearly in increasing 
order of importance. 
Mortality must remain the overriding criterion, not just 
because of its uniformity of measurement and clear primacy 
to the patient being treated, but because it constitutes a 
summation of the effects of immediate and sustained coro-
nary patency, of preservation of ventricular function and of 
the side effects associated with the use of all these drugs. 
Simply, it alone is the "best predictor" of mortality! 
Parenthetically, in this review I will refer only to survival 
data from studies with adequate randomized control arms. 
Reference to observed mortality from single-arm studies 
(with respect to thrombolytic therapy) as a reflection of 
thrombolytic efficacy without consideration of the baseline 
condition of the study group has no scientific validity. Such 
mortality data reflect multiple factors, including regional 
patient characteristics, enrollment criteria and their applica-
tion, physician approaches, concomitant drug and other 
therapies, and the specific effect of the pharmaceutical agent 
in question; thus, they should no more be argued (or 
JACC Vol. 18, No.6 
November 15, 1991:1573-8 
accepted) as evidence of drug effect than would a study 
reporting pulmonary capillary wedge pressure only during 
drug treatment (without baseline or randomized control 
data) as evidence of, for example, the efficacy of a vasodi-
lator in congestive heart failure. 
Clinical Studies 
Streptokinase. Streptokinase was the first of the available 
agents approved for intravenous administration for the treat-
ment of acute myocardial infarction. Angiographically dem-
onstrated reperrusion or patency rates have typically been 
approximately 50% to 60%, ranging from the low of 31% 
found in the TIMI-1 trial (9) to 81% in the study by Koren et 
a!. (10). In the Intravenous Streptokinase in Acute Myocar-
dial Infarction (ISAM) study (11), left ventricular systolic 
function (ejection fraction) was significantly better in pa-
tients treated with streptokinase than in control patients 
(56.8% ± 0. 7 vs. 53.9% ± 0. 7, p < 0.005). This difference 
was also seen in the study by White eta!. (12) (59 ± 10.5 vs. 
53 ± 13.5, p < 0.005). In this latter study mortality (30 day) 
was also significantly reduced (2.5% vs. 12.9%, p < 0.02). 
In the first GISSI (Gruppo Italiano per lo Studio della 
Streptochinasi nell' Infarto Miocardico) study, intravenous 
streptokinase led to significant reductions in mortality com-
pared to control early (21 days, 20% for those treated in 
<6 h) (13) and, importantly, late (1 year, 13% for those 
treated in <6 h) (14). In ISIS-2 (International Study of 
Infarct Survival) (15), streptokinase therapy within 6 h of 
pain onset led to a 27% reduction in mortality at 35 days. 
Recombinant tissue-type plasminogen activator. Recombi-
nant tissue-type plasminogen activator (rt-PA) is an endog-
enous activator of plasminogen produced normally by endo-
thelial cells. Enzymatically active single-chain (alteplase) 
and double-chain (duteplase) forms exist (16), the latter 
produced by cleavage of the former into a light and a heavy 
chain linked by a disulfide bond. 
Reported reperrusion and patency rates of 61% to 89% 
(17) have been higher than those reported for streptokinase. 
Preservation of ventricular function was demonstrated by 
O'Rourke et a!. (18) and others. 
The ASSET trial (Anglo-Scandinavian Study of Early 
Thrombolysis) (19) is the major survival trial for rt-PA; 
intravenous heparin was used as adjunctive therapy, a 
5,000 U bolus injection followed by infusion of 1,000 U/h 
after completion of the 3-h rt-P A infusion. Mortality at 
1 month in the rt-PA group was 26% below that for the 
control group and 13% below that of the control group at 
1 year (20). This led the investigators (19) to observe that 
" ... the superiority of rt-P A over streptokinase reported in 
coronary angiographic studies does not seem to be reflected 
in striking differences in fatality rates" given the compara-
bility of the results to those seen with the previously cited 
safety and survival trials of intravenous streptokinase. 
Anistreplase. Anistreplase (APSAC) was bioengineered 
by the in vitro binding of streptokinase to plasminogen, and 
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the complex was then anisoylated to retard its enzymatic 
degradation, resulting in the longest half-lifev of available 
agents. Bonnier et al. (21) demonstrated a coronary patency 
rate similar to that achieved with intracoronary streptoki-
nase (64% vs. 68%, p = NS), a short time (45 min) to 
patency, with only a 5% reocclusion rate. Bassand et al. (22), 
in addition to a 77% patency rate, found a 31% reduction in 
myocardial infarct size (by single-photon emission computed 
tomography [SPECT]) with salvage of left ventricular sys-
tolic function (ejection fraction 53% vs. 47%, p < 0.002). 
In the German multicenter trial (23), there was a 56% 
reduction in mortality (5.6% vs. 12.6%, p < 0.05) after 
administration of anistreplase. Similar findings came from 
the AIMS (APSAC Intervention Mortality Study) trial (24), 
which demonstrated a 47% reduction in 30-day mortality 
(6.4% vs. 12.2%, p < 0.002). Reduction in mortality at 1 year 
was 39% (25). 
Comparative Studies 
Several studies have directly compared the relative effi-
cacies of the available thrombolytic drugs. The TIMI-1 trial 
(9) probably influenced care in the United States more than 
any other single study. In this study, intravenous rt-PA (90% 
duteplase [26]) and intravenous streptokinase were com-
pared in a randomized double-blind study. The relative fibrin 
selectivity of rt-PA, despite significantly higher fibrinogen 
levels, and the shorter half-life of rt-PA afforded no advan-
tage in bleeding complications (27), which were equal in each 
group. The reperfusion rate at 90 min was significantly 
higher in the group treated with rt-PA than in the group 
treated with streptokinase (62% vs. 31%, p < 0.001). How-
ever, this difference did not translate into any significant 
differences in other clinical variables of outcome, either 
ventricular function or survival (28,29), although the study 
was too small to assess for differences in survival. 
European Cooperative Study Group. This difference was 
far greater than that seen in the European Cooperative Study 
Group for Recombinant Tissue-Type Plasminogen Activator 
trial (30), which demonstrated a strong trend to a statistically 
higher patency rate for rt-PA (also 90% duteplase) than for 
streptokinase (70% vs. 55%, p < 0.06). 
PAlMS. The Plasminogen Activator Italian Multicenter 
Study (PAlMS) (31), using nonangiographic indicators of 
reperfusion and later (4 days) angiographic patency, found 
equal sustained reperfusion with rt-PA (predominantly al-
teplase, as with all subsequent trials except ISIS-3) and 
streptokinase, and comparable rates oflate patency (81% vs. 
74%, p = NS). Left ventricular ejection fraction at angiog-
raphy was not significantly different between the two groups 
(55% vs. 53%). 
Other trials. White et a!. (32) also compared intravenous 
streptokinase and rt-P A in a study analyzing ventricular 
function. Aspirin and intravenous heparin were cotherapies. 
Late patency (3 weeks) did not differ between groups 
(76% vs. 75%, p = NS) and the rate ofreinfarction at 30 days 
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was the same (5%). Regardless of index used (ejection 
fraction, end-systolic volume, segmental wall motion) or 
infarct site (anterior vs. inferior) there were no significant 
differences between groups in ventricular function. Mortal-
ity was not significantly different, but the study was too 
small to assess for this end point. 
Charbonnier et a!. (33) reported higher patency rates at 
90 min with anistreplase than with streptokinase. Not unlike 
the results of the PAlMS trial, late patency was similar for 
streptokinase and anistreplase. The Thrombolytic Trial of 
Eminase in Acute Myocardial Infarction (TEAM-2) trial (34) 
reported similar rates of 4-h vessel patency (TIMI grade 2 to 
3 flow) with anistreplase and streptokinase but significantly 
higher rates of TIMI grade 3 flow with anistreplase, suggest-
ing more complete thrombolysis. 
Bassand eta!. (35) compared rt-PA and anistreplase in a 
double-blind trial and found equal effects on patency, ven-
tricular function and bleeding (despite significantly different 
resultant fibrinogen levels). Anderson et a!. (36) also found 
similar 24-h patency rates with rt-PA and anistreplase 
(85% VS. 90%, p = NS). 
GISSI-2. The most controversial comparative study has 
been the GISSI-2/International Study Group study (2,3), 
again comparing rt-PA and streptokinase. This two-tiered 
study ("2 x 2 factorial design"), performed in the aspirin era 
that followed the impressive results of ISIS-2, investigated 
two questions: 1) the relative efficacy of the two throm-
bolytic agents in reducing mortality, and 2) the possible 
incremental contribution of heparin (above that achievable 
with the uniformly administered cotherapy, aspirin). The 
heparin regimen, 12,500 U subcutaneously every 12 h start-
ing 12 h after initiation of thrombolytic therapy has been the 
focus of the controversy. 
In this study no significant difference was found between 
rt-PA and streptokinase in mortality (8.9% vs. 8.5%), and 
mortality was even numerically lower in the streptokinase 
group. Thus, this study confirmed the similar reductions in 
mortality seen in the GISSI-1, ISIS-2 and ASSET trials. 
However, there were significant differences in comorbidity. 
Overall, strokes occurred more commonly in patients 
treated with rt-PA (1.3% vs. 0.9%, p = 0.05), principally in 
those patients whose condition was categorized as hemor-
rhagic or undefined ("ischemic" strokes occurred equally in 
the two groups). This difference was comparable to the 
measured difference in survival. 
Overall, all other bleeding, both "major" and "minor," 
occurred more commonly in patients treated with rt-PA than 
in those receiving streptokinase, whereas "major" bleeding 
(requiring more than a 2 U transfusion) was more common in 
the streptokinase group. Allergic reactions were statistically 
more common in the streptokinase group (0.2% vs. 1.7%). 
High dose subcutaneous heparin was found to effect no 
advantage in either the rt-PA or the streptokinase arms but 
was associated with an excess in bleeding complications. 
The HART trial. The use of a delayed and nonintrave-
nous heparin regimen has been criticized, and the HART 
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trial (l), as discussed, has been the central study to support 
this. Its finding of significantly different patency rates be-
tween the heparin and low dose aspirin groups has been 
interpreted to show that rt-PA efficacy is dependent on 
concurrent intravenous heparin administration and that the 
GISSI-2 study is thus fatally flawed and should be either 
discarded or repeated. 
However, the use of low dose aspirin (80 mg) limits the 
comparability of the trial to the GISSI-2 study, in which full 
dose aspirin (300 to 325 mg) was used in 96% of patients. 
There have been no major clinical end point trials of the 
efficacy of this low dose regimen (37); the lowest dose of 
aspirin proved clinically efficacious was the 160 mg dose 
used in ISIS-2. Although one group (38) studying normal 
volunteers with 100 mg aspirin found near complete platelet 
thromboxane B2 synthesis inhibition at 24 h after dosing, 
another (39) found that high degree inhibition required 
cumulative dosing for several days. How these findings 
would apply to infarct size and mortality reduction in pa-
tients with unstable coronary disease and the hemodynamic 
and circulatory derangements associated with acute myocar-
dial infarction can only be hypothesized. 
In unstable angina, where the unstable coronary plaque 
typically also has associated intracoronary thrombus (40), no 
statistical difference was found between full dose aspirin and 
heparin (41). By contrast, it would appear from the HART 
trial that the 80 mg dose is relatively clinically inefficacious. 
European Cooperative Study Group 6 trial. The editorial 
(5) accompanying the study of Hsia et al. (l) observed that 
similar results had been found in the European Cooperative 
Study Group 6 trial with a higher dose of aspirin. But this 
was a comparison of full dose loading aspirin followed again 
by low dose (on alternate days only) aspirin and randomiza-
tion between intravenous heparin and no heparin. The 
incremental patency effect of intravenous heparin with this 
was less impressive (83% vs. 75%, p < 0.01), and no data are 
provided for ultimate effects on survival, the end point of 
GISSI-2. 
Neither of these trials used aspirin doses equivalent to 
those in GISSI-2, which have been proved clinically effica-
cious in multiple prior studies (37); none address ultimate 
effects of this therapy (e.g., survival), and, most impor-
tantly, none provide any streptokinase arm to suggest that 
the observed benefits are unique to rt-PA. 
Comments 
Role of adjunctive therapy with heparin. The results of 
the HART and European Cooperative Study Group 6 trials 
would be cautionary to GISSI-2 only if one treatment arm 
(i.e., rt-PA) was uniquely disadvantaged compared with the 
other, and there is no study offering evidence to this effect. 
Several studies (31,32) have shown comparable late patency 
of rt-PA and streptokinase despite the early advantage 
demonstrated with rt-PA in TIMI-1. This result would sug-
gest that streptokinase may be equally dependent (and 
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possibly more so) on anticoagulant coverage with heparin for 
this "catch-up" in observed patency. 
In fact, Mahan et al. (42) have demonstrated that vessel 
patency with streptokinase is dependent on concomitant 
heparin therapy, both for maintaining initial patency and for 
late developing patency (i.e., catch-up patency). Potentially 
improved vessel patency with adjunctive heparin therapy is 
not unique to rt-PA. 
The measured mortality in GISSI-2 in the patients treated 
with rt-PA and heparin was higher than for those treated 
with rt-PA without heparin. This observation is opposite to 
that for the streptokinase-treated group, and contradicts the 
hypothesis of a unique dependence of rt-PA on heparin for 
efficacy. Although this difference of effect might be second-
ary to artifacts in randomization, one would have anticipated 
a trend to benefit. Furthermore, reinfarction (a postulated 
clinically resulting sequela of "inadequate" heparinization) 
occurred numerically more commonly (2.6% vs. 3.0%, p = 
NS) in the streptokinase-treated group, a finding also arguing 
against a unique dependence of rt-PA on concomitant hep-
arin administration. While none of these achieved statistical 
significance, none were directionally consonant (i.e., a 
"trend") with the hypothesis that the heparin regimen 
employed was uniquely prejudicial against rt-PA. Indeed, as 
observed earlier, the results of the GISSI-2 trial were con-
sistent with the body of existent data (i.e., the preceding 
safety and efficacy survival trials). 
Aspirin versus heparin: ISIS-3. Finally, while only pre-
liminarily presented at the recent American College of 
Cardiology scientific sessions, the ISIS-3 trial further con-
firms the preceding studies. A direct, randomized compari-
son of streptokinase, recombinant tissue plasminogen acti-
vator (duteplase), and anistreplase, this trial found no 
significant difference among these agents in mortality after 
their use for acute myocardial infarction (10.5%, 10.3% and 
10.6%, respectively). 
Administering the subcutaneous heparin at completion of 
the rt-PA infusion in ISIS-3 did not lead to different results 
from those of the delayed regimen of GISSI-2. The addition 
of heparin to "thrombolysis plus aspirin" (the standard of 
care since ISIS-2) reduced absolute mortality by 0.5% 
(7% vs. 7.5%, p = 0.03 at 7 days; 10% vs. 10.5%, p = NS at 
35 days). But major (transfusion-requiring) bleeding in-
creased by 0.3% with the addition of heparin, and intracere-
bral hemorrhage by 0.2% (0.1% increase in total strokes). In 
contrast, in ISIS-2 aspirin improved thrombolysis-reduced 
mortality by almost five times the improvement achieved in 
ISIS-3 with heparin (2.4% [9.4% vs. 11.8%]) with no increase 
in major bleeding and a 0.4% reduction in strokes. Clearly, 
the benefit/risk ratio of adding heparin to thrombolysis plus 
aspirin is far lower than that of adding aspirin to thrombol-
ysis, and far more complex than vessel patency indexes 
alone would reflect. 
ISIS-3 directly compares the three approved drugs for 
intravenously administered thrombolysis and provides fur-
ther information as to their relative efficacy. Rather than 
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being preemptively discounted to support established con-
victions, its findings should be approached with enormous 
interest. Although smaller trials may illustrate the pharma-
cologic actions of various drugs, appropriately sized survival 
trials will always be required to assess the ultimate effects, 
as survival more completely reflects the total action (proxi-
mal and distant therapeutic effects versus side effects) of the 
treatment. 
Summary 
The past decade has seen an unprecedented investiga-
tional effort to understand and apply a revolutionary new 
approach to the treatment of the leading cause of death. This 
effort has required a reevaluation of traditional concepts and 
approaches. However, it would be unreasonable to expect 
that conclusions from the 1st 5 years of such study would 
remain unshaken by the inevitably more focused studies that 
have and will follow. As new agents (scu-PA, for example) 
and new concomitant therapies such as hirudin are devel-
oped it can only be anticipated that the approach to the 
patient with acute myocardial infarction will change. 
Currently three available thrombolytic activators are ap-
proved for the therapy of acute myocardial infarction. Each 
of these has been shown to reduce significantly the mortality 
associated with acute myocardial infarction. After the 
TIMI-1 trial, it was hypothesized that the early patency 
advantage ofrt-PA over streptokinase would be a consistent 
finding (over streptokinase and over other drugs), and that it 
would translate equally into advantages in survival. 
Despite multiple trials evaluating this issue, both those 
comparing drug against placebo and one drug against an-
other, the striking superiority of rt-PA in patency demon-
strated in TIMI-1 has not been confirmed, and has not 
resulted in a measurable advantage in survival outcome. 
However, in a reversal of traditional scientific method, these 
findings, rather than leading to a reexamination of the initial 
hypothesis, have been followed by critical reexamination 
(and rejection) of the completed trials. 
This field has been dominated by research committed to 
this hypothesis. Review has often lacked true independence 
and has promoted articles consonant with the hypothesis and 
rejected those antithetical to it. The recent handling of the 
HART and GISSI-2 trials (and the just presented ISIS-3 trial, 
even before release of its results) typify this. 
What have been hypotheses will undergo focused scien-
tific study of their validity. Testing serves to validate hypoth-
eses, not the inverse. New data must continually be re-
viewed openly, critically and independently. The scientific 
medical community, and particularly the medical journals, 
must assure that the data are critically reviewed by indepen-
dent investigators and presented in a balanced fashion. 
Rigorous criteria to assure scientific independence in edito-
rial review similarly must be followed. Only thus can we 
assure the quality of scientific inquiry. 
It is proposed that standards of review and editorial 
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comment mandating true critical distance and independence 
be followed. By such, greater independence of scientific 
inquiry, review and debate may result. 
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